Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO® in Acute Otitis Media with Tympanostomy Tubes

Back to Jobs

SAN DIEGO , June 22, 2017 (GLOBE NEWSWIRE) — Otonomy , Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced that it it has successfully completed an End-of-Phase 2 review

Apply Now